Outcome and Minimal Residual Disease Monitoring in t(16;21) Acute Myeloid Leukemia Patients Receiving Allogeneic Hematologic Stem Cell Transplantation
• t(16;21) AML is an indication for allo-HSCT.• The TLS-ERG transcript levels reflected MRD and may predict relapse after HSCT.• The TLS-ERG transcript levels might guide effective intervention.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Ya-Zhen Qin, Yao Chen, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Huan Chen, Xiao-Su Zhao, Kai-Yan Liu, Xiao-Jun Huang Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Biology | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Transplants